Preferential HER‐2/neu overexpression and/or amplification in aggressive histological subtypes of invasive breast cancer
- 26 March 2004
- journal article
- Published by Wiley in Histopathology
- Vol. 44 (4) , 332-338
- https://doi.org/10.1111/j.1365-2559.2004.01843.x
Abstract
To investigate whether alterations of the HER2 gene occur more frequently in histologically unfavourable subtypes of invasive breast cancer. The study was composed of nine invasive apocrine, six lipid-rich, 12 glycogen-rich, 11 micropapillary and 33 pleomorphic lobular breast carcinomas. Lymph node involvement was represented in all subgroups. HER2 status was confirmed in all cases by using immunohistochemistry (CB11, Herceptest) and fluorescent in-situ hybridization (FISH) analysis (Vysis). Micropapillary and apocrine carcinomas showed the highest rate of protein overexpression (72% and 66%) and gene amplification (45% and 44%). Protein overexpression was common in poorly differentiated pleomorphic lobular carcinomas (56%); however, this subgroup failed to show an increased number of gene copies by FISH (31%). The incidence of HER2 overexpression (33% and 50%, respectively) and gene amplification (25% and 33%, respectively) among glycogen-rich and lipid-rich carcinomas was not higher than that observed in breast cancer generally. Our data suggest that preferential involvement of the HER2 gene in micropapillary and apocrine breast carcinomas may contribute to their aggressive behaviour.Keywords
This publication has 21 references indexed in Scilit:
- Histological and immunohistochemical analysis of apocrine breast carcinomaBreast Cancer, 2002
- Evaluating HER2 amplification and overexpression in breast cancerThe Journal of Pathology, 2001
- Clinicopathologic Analysis of Invasive Micropapillary Differentiation in Breast CarcinomaLaboratory Investigation, 2001
- Breast CancerThe Oncologist, 2001
- Invasive micropapillary carcinoma of the breast: Eighty cases of an underrecognized entityHuman Pathology, 2001
- Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2New England Journal of Medicine, 2001
- Laboratory assessment of the status of Her-2/neu protein and oncogene in breast cancer specimens: comparison of immunohistochemistry assay with fluorescence in situ hybridisation assaysJournal of Clinical Pathology, 2000
- Sensitivity of HER-2/neu Antibodies in Archival Tissue Samples of Invasive Breast CarcinomasAmerican Journal of Clinical Pathology, 2000
- Estrogen and Progesterone Receptors, C-ERBB-2, p53, and BCL-2 in Thirty-three Invasive Micropapillary Breast CarcinomasPathology - Research and Practice, 1996
- Relation between apocrine differentiation and receptor status, prognosis and hormonal response in breast cancerEuropean Journal of Cancer and Clinical Oncology, 1990